FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4238554661> ?p ?o ?g. }

• W4238554661 abstract "ABSTRACT Background In early January 2021, an outbreak of nosocomial cases of COVID-19 emerged in Western France, with RT-PCR tests repeatedly negative on nasopharyngeal samples but positive on lower respiratory tract samples. Whole genome sequencing (WGS) revealed a new variant, currently defining a novel SARS-CoV-2 lineage: B.1.616. In March, WHO classified this variant as ‘under investigation’ (VUI). We analyzed the characteristics and outcomes of COVID-19 cases related to this new variant. Methods Clinical, virological, and radiological data were retrospectively collected from medical charts in the two hospitals involved. We enrolled patients with at least one of the following: i) positive SARS-CoV-2 RT-PCR on a respiratory sample; ii) seroconversion with anti-SARS-CoV-2 IgG/IgM; iii) suggestive symptoms and typical features of COVID-19 on chest CT scan. Cases were categorized as either: i) B.1.616; ii) variant of concern (VOC); iii) unknown. Findings From January 1 st to March 24 th , 2021, 114 patients fulfilled the inclusion criteria: B.1.616 (n=34), VOC (n=32), and unknown (n=48). B.1.616-related cases were older than VOC-related cases (81 years [73-88], vs 73 years [67-82], P <0.05) and their first RT-PCR tests were less often positive (5/34, 15% vs 31/32, 97%, P <0.05). The B.1.616 variant was independently associated with severe disease (multivariable Cox model HR 4.2 [1.3– 13.5], P =0.018), and increased lethality (logrank test P =0.01): 28-day mortality 15/34 (44%) with B.1.616, vs. 5/32 (16%) for VOC, P =0.036. Interpretation We report a nosocomial outbreak of COVID-19 cases related to a new variant, B.1.616, poorly detected by RT-PCR on nasopharyngeal samples, with high lethality. Research in context Evidence before this study Among the numerous SARS-CoV-2 variants described worldwide, only 3 are currently classified as Variant of Concern (VOC) by the WHO, since they are associated with either an increased risk in transmissibility, severity, or significant reduction in neutralization by antibodies: B.1.1.7, B.1.351 and P.1 (Pango lineage nomenclature). With the ongoing circulation of SARS-CoV-2 in many places worldwide, the emergence of new variants may reduce the efficacy of vaccines and jeopardize our prospects to control the pandemic. In early January 2021, an outbreak of cases highly suggestive of COVID-19 despite negative RT-PCR tests on repeated nasopharyngeal (NP) samples was reported in Western France, leading to several nosocomial clusters. Whole-genome sequencing (WGS) from lower respiratory tract samples identified a new lineage of SARS-CoV-2 virus, classified as B1.616. Consequently, the French public health agency (Santé publique France) and the WHO classified B.1.616 as ‘variant under investigation’ (VUI). Added value of this study Our observational study, conducted from January 1 st to March 24 th 2021 in the B.1.616 identified area, provides the first clinical and virological description of B.1.616-associated COVID-19. The 34 cases had clinical, biological and radiological findings in line with classical features of COVID-19, while RT-PCR tests on nasopharyngeal (NP) samples failed to detect SARS-CoV-2 in most patients. Indeed, this gold-standard test was positive in only 15% of the first tests in B.1.616-related COVID-19 patients. Of note, the diagnostic performance of RT-PCR tests was satisfactory on lower respiratory tract samples, suggesting that failure to detect B.1.616 on NP samples would be due to a viral load below the limit of detection in the upper respiratory tract, rather than to genomic mismatches between routine RT-PCR targets and this variant. In our cohort, B.1.616 was independently associated with worse clinical outcome, with high 28-day mortality (44%). Implications of all the available evidence Diagnosis of B.1.616-related COVID-19 cases should not rely on RT-PCR tests on NP samples. In the epidemic area, strict infection control measures must be maintained as long as COVID-19 diagnosis is not ruled out, in order to limit nosocomial clusters and case fatality. Further studies are needed to confirm and investigate the association between genomic characteristics of B.1.616, and i) poor detection by RT-PCR tests on NP samples; ii) prognosis." @default.
• W4238554661 created "2022-05-12" @default.
• W4238554661 creator A5001921696 @default.
• W4238554661 creator A5009000262 @default.
• W4238554661 creator A5009276849 @default.
• W4238554661 creator A5013383952 @default.
• W4238554661 creator A5017897802 @default.
• W4238554661 creator A5021684077 @default.
• W4238554661 creator A5028862560 @default.
• W4238554661 creator A5030750494 @default.
• W4238554661 creator A5030887506 @default.
• W4238554661 creator A5031403230 @default.
• W4238554661 creator A5036541096 @default.
• W4238554661 creator A5037100913 @default.
• W4238554661 creator A5039272561 @default.
• W4238554661 creator A5041062231 @default.
• W4238554661 creator A5054104276 @default.
• W4238554661 creator A5055755279 @default.
• W4238554661 creator A5067253433 @default.
• W4238554661 creator A5067653881 @default.
• W4238554661 creator A5068589059 @default.
• W4238554661 creator A5068751805 @default.
• W4238554661 creator A5069063356 @default.
• W4238554661 creator A5069095081 @default.
• W4238554661 creator A5072424819 @default.
• W4238554661 creator A5073081133 @default.
• W4238554661 creator A5074205773 @default.
• W4238554661 creator A5082020357 @default.
• W4238554661 creator A5082732173 @default.
• W4238554661 creator A5086202483 @default.
• W4238554661 date "2021-05-10" @default.
• W4238554661 modified "2023-10-18" @default.
• W4238554661 title "A new SARS-CoV-2 variant poorly detected by RT-PCR on nasopharyngeal samples, with high lethality" @default.
• W4238554661 cites W2108234281 @default.
• W4238554661 cites W2113679889 @default.
• W4238554661 cites W2119775949 @default.
• W4238554661 cites W2129542667 @default.
• W4238554661 cites W2131271579 @default.
• W4238554661 cites W2616925143 @default.
• W4238554661 cites W3016535995 @default.
• W4238554661 cites W3034858522 @default.
• W4238554661 cites W3036252633 @default.
• W4238554661 cites W3036912690 @default.
• W4238554661 cites W3043124965 @default.
• W4238554661 cites W3049233984 @default.
• W4238554661 cites W3083985591 @default.
• W4238554661 cites W3085629533 @default.
• W4238554661 cites W3087744389 @default.
• W4238554661 cites W3111916089 @default.
• W4238554661 cites W3121995178 @default.
• W4238554661 cites W3125038587 @default.
• W4238554661 cites W3126729284 @default.
• W4238554661 cites W3127852352 @default.
• W4238554661 cites W3129869280 @default.
• W4238554661 cites W3130126061 @default.
• W4238554661 cites W3133980772 @default.
• W4238554661 cites W3134208712 @default.
• W4238554661 cites W3137149656 @default.
• W4238554661 cites W3148277587 @default.
• W4238554661 cites W4210642183 @default.
• W4238554661 doi "https://doi.org/10.1101/2021.05.05.21256690" @default.
• W4238554661 hasPublicationYear "2021" @default.
• W4238554661 type Work @default.
• W4238554661 citedByCount "5" @default.
• W4238554661 countsByYear W42385546612021 @default.
• W4238554661 countsByYear W42385546612022 @default.
• W4238554661 crossrefType "posted-content" @default.
• W4238554661 hasAuthorship W4238554661A5001921696 @default.
• W4238554661 hasAuthorship W4238554661A5009000262 @default.
• W4238554661 hasAuthorship W4238554661A5009276849 @default.
• W4238554661 hasAuthorship W4238554661A5013383952 @default.
• W4238554661 hasAuthorship W4238554661A5017897802 @default.
• W4238554661 hasAuthorship W4238554661A5021684077 @default.
• W4238554661 hasAuthorship W4238554661A5028862560 @default.
• W4238554661 hasAuthorship W4238554661A5030750494 @default.
• W4238554661 hasAuthorship W4238554661A5030887506 @default.
• W4238554661 hasAuthorship W4238554661A5031403230 @default.
• W4238554661 hasAuthorship W4238554661A5036541096 @default.
• W4238554661 hasAuthorship W4238554661A5037100913 @default.
• W4238554661 hasAuthorship W4238554661A5039272561 @default.
• W4238554661 hasAuthorship W4238554661A5041062231 @default.
• W4238554661 hasAuthorship W4238554661A5054104276 @default.
• W4238554661 hasAuthorship W4238554661A5055755279 @default.
• W4238554661 hasAuthorship W4238554661A5067253433 @default.
• W4238554661 hasAuthorship W4238554661A5067653881 @default.
• W4238554661 hasAuthorship W4238554661A5068589059 @default.
• W4238554661 hasAuthorship W4238554661A5068751805 @default.
• W4238554661 hasAuthorship W4238554661A5069063356 @default.
• W4238554661 hasAuthorship W4238554661A5069095081 @default.
• W4238554661 hasAuthorship W4238554661A5072424819 @default.
• W4238554661 hasAuthorship W4238554661A5073081133 @default.
• W4238554661 hasAuthorship W4238554661A5074205773 @default.
• W4238554661 hasAuthorship W4238554661A5082020357 @default.
• W4238554661 hasAuthorship W4238554661A5082732173 @default.
• W4238554661 hasAuthorship W4238554661A5086202483 @default.
• W4238554661 hasBestOaLocation W42385546611 @default.
• W4238554661 hasConcept C116675565 @default.
• W4238554661 hasConcept C126322002 @default.
• W4238554661 hasConcept C159047783 @default.
• W4238554661 hasConcept C2522874641 @default.

• next